efonidipine has been researched along with deferasirox in 1 studies
| Studies (efonidipine) | Trials (efonidipine) | Recent Studies (post-2010) (efonidipine) | Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) |
|---|---|---|---|---|---|
| 129 | 18 | 30 | 832 | 136 | 572 |
| Protein | Taxonomy | efonidipine (IC50) | deferasirox (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 6B | Homo sapiens (human) | 3.95 | |
| Lysine-specific demethylase 4A | Homo sapiens (human) | 3.77 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
1 other study(ies) available for efonidipine and deferasirox
| Article | Year |
|---|---|
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |